Fulcrum Therapeutics (FULC) Operating Margin (2020 - 2024)
Historic Operating Margin for Fulcrum Therapeutics (FULC) over the last 5 years, with Q2 2024 value amounting to 65.61%.
- Fulcrum Therapeutics' Operating Margin rose 31669800.0% to 65.61% in Q2 2024 from the same period last year, while for Dec 2024 it was 27.37%, marking a year-over-year increase of 39178700.0%. This contributed to the annual value of 27.37% for FY2024, which is 39178700.0% up from last year.
- Per Fulcrum Therapeutics' latest filing, its Operating Margin stood at 65.61% for Q2 2024, which was up 31669800.0% from 3213.78% recorded in Q4 2023.
- Over the past 5 years, Fulcrum Therapeutics' Operating Margin peaked at 65.61% during Q2 2024, and registered a low of 9471.19% during Q1 2023.
- Moreover, its 5-year median value for Operating Margin was 1033.77% (2020), whereas its average is 2044.08%.
- In the last 5 years, Fulcrum Therapeutics' Operating Margin crashed by -84681800bps in 2023 and then skyrocketed by 31669800bps in 2024.
- Over the past 5 years, Fulcrum Therapeutics' Operating Margin (Quarter) stood at 420.99% in 2020, then fell by -11bps to 465.78% in 2021, then tumbled by -777bps to 4083.65% in 2022, then rose by 21bps to 3213.78% in 2023, then soared by 102bps to 65.61% in 2024.
- Its last three reported values are 65.61% in Q2 2024, 3213.78% for Q4 2023, and 3615.28% during Q3 2023.